Podcasts about MSC

Today, I am delighted to reconnect with two previous guests, Dr. Darren Candow. Dr. Candow is a distinguished professor and an internationally renowned researcher on creatine monohydrate, nutrition, and physical activity, whom I had the pleasure of speaking with on Episode 301, where we discussed creatine.  We are doing an AMA session today, delving into various themes surrounding creatine, from debunking outdated RDA recommendations to exploring the synergies between strength training and creatine efficacy. We examine the cognitive benefits of creatine, investigating its interactions with caffeine and its implications for bone health, hydration, anabolic resistance, and metabolic health.  You will find today's AMA session as enlightening and enriching as I did while recording it. IN THIS EPISODE YOU WILL LEARN: The safety and efficacy of creatine as a supplement How creatine increases muscle mass and reduces protein catabolism The benefits of combining creatine with protein  Is it better to take creatine before or after a workout? How creatine supplementation may improve brain performance and mental clarity Why exercise is essential for those who want to experience the benefits of creatine for maintaining their bone health The benefits of resistance-band workouts for post-menopausal women Are there any age-related limits for creatine supplementation? Bio: Dr. Darren Candow Dr. Darren Candow, PhD, CSEP-CEP, is Professor and Director of the Aging Muscle and Bone Health Laboratory in the Faculty of Kinesiology and Health Studies at the University of Regina, Canada. The overall objectives of Dr. Candow's research program are to develop effective lifestyle interventions that incorporate nutrition (primarily creatine monohydrate) and physical activity (resistance training), with practical and clinical relevance for improving musculoskeletal aging and reducing the risk of falls and fractures. Dr. Candow has published over 120 peer-refereed journal manuscripts, supervised over 20 MSc and PhD students, and received research funding from the Canadian Institutes of Health Research, Canada Foundation for Innovation, the Saskatchewan Health Research Foundation, the National Institute of Health, and the Nutricia Research Foundation. In addition, Dr. Candow serves on the editorial review boards for the Journal of the International Society of Sports Nutrition, Nutrients, and Frontiers. Connect with Cynthia Thurlow Follow on X ⁠Instagram⁠ ⁠LinkedIn⁠ Check out Cynthia's ⁠website⁠ Submit your questions to ⁠support@cynthiathurlow.com⁠ Connect with Dr. Darren Candow On⁠ Instagram⁠ and X  Previous Episode Mentioned: ⁠Ep. 301 Creatine: The Best Supplement for Better Bones & Brain Health with Darren Candow, PhD, CSEP-CEP⁠

Natalie Lawrence is an author and illustrator who explores our relationship with the natural world, looking through multiple lenses - from the biological to the mythic and psychoanalytic. She completed a MSc and Ph.D. in History and Philosophy of Science at Cambridge, exploring the making and meanings of monstrous creatures in seventeenth century Europe. She published her first book as a teenager, Feathers and Eggshells, inspired by Hampstead Heath and the birds she was entranced by as a child, and published Planta Sapiens with Paco Calvo in 2022. She has also given a TedX talk, appeared on BBC Radio, and worked with installation artists.  In this chat, we talk about humans' fascination for monsters, how the walrus was originally conceived of as being a monster, the Hydra of Hamburg, cryptids as contemporary monsters and the ways in which our understanding of what is real and what exists has changed over the centuries. Buy Enchanted Creatures: Our Monsters and Their Meanings: https://uk.bookshop.org/a/12992/9781474619035 Find Natalie on Instagram: https://www.instagram.com/natalie.j.lawrence/ And her website: https://nataliejlawrence.com/ Get your free guide to home protection the folklore way here: https://www.icysedgwick.com/fab-folklore/ Become a member of the Fabulous Folklore Family for bonus episodes and articles at https://patreon.com/bePatron?u=2380595 Buy Icy a coffee or sign up for bonus episodes at: https://ko-fi.com/icysedgwick Fabulous Folklore Bookshop: https://uk.bookshop.org/shop/fabulous_folklore Pre-recorded illustrated talks: https://ko-fi.com/icysedgwick/shop Request an episode: https://forms.gle/gqG7xQNLfbMg1mDv7 Get extra snippets of folklore on Instagram at https://instagram.com/icysedgwick Find Icy on BlueSky: https://bsky.app/profile/icysedgwick.bsky.social 'Like' Fabulous Folklore on Facebook: https://www.facebook.com/fabulousfolklore/

Wolfgang and Jack are joined by : Martin Roberge, MSc, CFA - Managing Director | North American Portfolio Strategist at Canaccord Genuity Wolfgang G. Kruning - President & CEO, GBSC 360 Inc.

Exploring the Efficacy of BMAC and ADSC Injections in Knee Osteoarthritis   Hosts: David Rosenblum,MD Overview: In this episode, we delve into a recent study published in the Indian Journal of Orthopaedics that compares the therapeutic efficacy of Bone Marrow Aspirate Concentrate (BMAC) and Adipose-Derived Stem Cells (ADSCs) for treating knee osteoarthritis (OA). The study aims to provide insights into the effectiveness of these regenerative treatments and their correlation with mesenchymal stem cell (MSC) cellularity. Key Points Discussed: Background on Osteoarthritis: Definition and impact of OA, particularly in older populations. Overview of traditional treatments and the shift towards regenerative medicine. Study Objectives: To compare the efficacy of BMAC and ADSC injections in symptomatic knee OA patients. To analyze MSC quantity and quality in harvested tissues from both sources. Methodology: Description of the study design involving 60 patients with knee OA. Details on patient demographics, injection protocols, and follow-up assessments (VAS, WOMAC, ROM). Results: Significant improvements in clinical scores for both BMAC and ADSC groups at 6 months. Discussion on the lack of significant correlation between MSC quantity and treatment efficacy. Insights into the success rates of MSC cultures from both bone marrow and adipose tissue. Conclusions: Both treatments demonstrated clinical improvements, with no substantial differences between them. BMAC showed higher MSC counts and faster recovery rates, but further research is needed to understand the underlying factors affecting efficacy. Implications for Clinical Practice: Considerations for clinicians when choosing between BMAC and ADSC treatments. Future directions for research in regenerative therapies for knee OA. References: Vitali, M., Ometti, M., Montalbano, F., et al. (2025). Bone Marrow Aspirate Concentrate (BMAC) Versus Adipose-Derived Stem Cells (ADSCs) Intra-articular Injection Therapeutic Efficacy in Knee OA Correlated to Their Mesenchymal Stem Cell (MSC) Cellularity: An Exploratory Comparative Pilot Study. Indian Journal of Orthopaedics. https://doi.org/10.1007/s43465-025-01525-z Listener Engagement: Join the conversation! Share your thoughts on BMAC and ADSC treatments for knee OA on social media using #JournalClubPodcast. Don't forget to subscribe for more discussions on the latest research in orthopaedics and regenerative medicine.

Exploring the Efficacy of BMAC and ADSC Injections in Knee Osteoarthritis   Hosts: David Rosenblum,MD Overview: In this episode, we delve into a recent study published in the Indian Journal of Orthopaedics that compares the therapeutic efficacy of Bone Marrow Aspirate Concentrate (BMAC) and Adipose-Derived Stem Cells (ADSCs) for treating knee osteoarthritis (OA). The study aims to provide insights into the effectiveness of these regenerative treatments and their correlation with mesenchymal stem cell (MSC) cellularity. Key Points Discussed: Background on Osteoarthritis: Definition and impact of OA, particularly in older populations. Overview of traditional treatments and the shift towards regenerative medicine. Study Objectives: To compare the efficacy of BMAC and ADSC injections in symptomatic knee OA patients. To analyze MSC quantity and quality in harvested tissues from both sources. Methodology: Description of the study design involving 60 patients with knee OA. Details on patient demographics, injection protocols, and follow-up assessments (VAS, WOMAC, ROM). Results: Significant improvements in clinical scores for both BMAC and ADSC groups at 6 months. Discussion on the lack of significant correlation between MSC quantity and treatment efficacy. Insights into the success rates of MSC cultures from both bone marrow and adipose tissue. Conclusions: Both treatments demonstrated clinical improvements, with no substantial differences between them. BMAC showed higher MSC counts and faster recovery rates, but further research is needed to understand the underlying factors affecting efficacy. Implications for Clinical Practice: Considerations for clinicians when choosing between BMAC and ADSC treatments. Future directions for research in regenerative therapies for knee OA. References: Vitali, M., Ometti, M., Montalbano, F., et al. (2025). Bone Marrow Aspirate Concentrate (BMAC) Versus Adipose-Derived Stem Cells (ADSCs) Intra-articular Injection Therapeutic Efficacy in Knee OA Correlated to Their Mesenchymal Stem Cell (MSC) Cellularity: An Exploratory Comparative Pilot Study. Indian Journal of Orthopaedics. https://doi.org/10.1007/s43465-025-01525-z Listener Engagement: Join the conversation! Share your thoughts on BMAC and ADSC treatments for knee OA on social media using #JournalClubPodcast. Don't forget to subscribe for more discussions on the latest research in orthopaedics and regenerative medicine.

La ampliación del aeropuerto de Málaga hasta los 36 millones de pasajeros. La junta pretende licitar a principios de 2026 el proyecto de ampliación de la Ciudad de la Justicia de Málaga, cuya nueva imagen quiere presentar antes de que acabe este año. La compañía naviera de cruceros MSC cerrará este año con 90.000 pasajeros en el puerto de Málaga. Benagalbón acoge este sábado la trigésima edición del concurso tradicional de verdiales. En deportes, el Unicaja buscará hoy a las 14h peninsular sella el pase a la final de la copa internacional ante el conjunto japonés Utsunomiya Brex y el Málaga afrontará el derbi en la Rosaleda ante el Cádiz. En nuestra entrevista de hoy hablamos con María José Domingo, psicóloga y presidenta de AFA, para celebrar el día mundial del Alzheimer que es este domingo.Escuchar audio

We know how important it is to be inspired by both big businesses and individuals, which is why we are excited to present Talking Leaders, a monthly initiative from the AHDB which will see a series of inspirational speakers share their life experiences and deliver impactful stories to the AgriLeader community.In the September episode of Talking Leaders, we are delighted to be joined by the new AHDB Chair: Emily Norton. Emily is a Norfolk farmer, Nuffield scholar and founder of Farm Foresight Ltd, a strategic advisory service for the rural sector.She has 25 years of experience in the food and farming sector. After qualifing as a lawyer, Emily undertook an MSc in Sustainable Agriculture. Her career has taken her from family business to global PLC, with time spent in Brussels and across the UK. Emily has particular expertise in natural capital influences on land, food and farming.Emily holds various non-executive board positions in the agricultural sector including chair of AHDB and a trustee at the Royal Norfolk Agricultural Association. She is a well known media commentator and lives and farms in Norfolk.

España recibió en agosto 11,7 millones de pasajeros internacionales, un 5,4 % más que en el mismo mes de 2024, según Turespaña. Entre enero y agosto el total asciende a 75,4 millones, con Reino Unido como principal emisor y aumentos destacados desde mercados como China, Corea del Sur, Brasil, Argentina y Colombia.La española Global Exchange se ha convertido en la mayor empresa de cambio de moneda del mundo, superando a la británica Travelex. La compañía opera ya en 84 aeropuertos y alcanza presencia en 30 países, tras su reciente entrada en Japón.Aena invertirá 12.888 millones de euros en los aeropuertos españoles entre 2027 y 2031, más del triple que en el periodo anterior. El plan, anunciado por el presidente del Gobierno, Pedro Sánchez, prioriza atender el aumento del tráfico aéreo, mejorar la experiencia de los pasajeros y reforzar la sostenibilidad ambiental.El interés por la movilidad sostenible en España creció un 190 % en 2025, con Madrid y Barcelona liderando la adopción de bicicletas y servicios de carsharing eléctricos. Un estudio de Semrush sobre 5 millones de consultas online refleja que ciudades como Zaragoza, Valencia, Sevilla y Bilbao también muestran un aumento de interés, mientras que el perfil de usuario incluye tanto mayores de 45 años como jóvenes interesados en patinetes eléctricos.La temporada de cruceros 2025-2026 consolida a España como puerto clave en Europa, con Barcelona, Málaga, Palma y Vigo como principales puntos de embarque. Navieras como Marella, Costa, MSC, Royal Caribbean y NCL reforzarán itinerarios y flota, apostando por buques más eficientes y la diversificación de destinos en el Mediterráneo y el Atlántico.Turkish Airlines ha comenzado a operar vuelos a Sevilla, que se convierte en su sexto destino en España tras Madrid, Barcelona, Valencia, Málaga y Bilbao. La aerolínea amplía así su conectividad en el sur de Europa, ofreciendo nuevas oportunidades para el turismo y los negocios.

Matt Zemon, MSc, is an educator, author, and leader in psychedelic wellness who focuses on the impact of psychedelics on mental health. He is the best-selling author of Psychedelics for Everyone, Beyond the Trip, and The Veteran's Guide to Psychedelics. His work centers on expanding access to psychedelic therapies, supporting veterans, and helping people find purpose, connection, and healing. In this episode… Psychedelics have moved from counterculture to boardroom, and more entrepreneurs are turning to them for healing and personal growth. But can these substances really transform the way business leaders think, feel, and lead? According to Matt Zemon, a bestselling author and educator in psychedelic wellness, the answer is yes. He explains how a guided journey helped him reconnect with his late mother, opening the door to profound emotional healing. He highlights the importance of mindset, environment, and source when approaching these medicines responsibly. For Matt, psychedelics didn't just shift his inner world; they made him a more present father, a more grounded entrepreneur, and an advocate for veterans and others seeking transformation. Tune in to this episode of the Smart Business Revolution Podcast as John Corcoran interviews Matt Zemon, an educator, author, and leader in psychedelic wellness, to discuss how psychedelics are helping entrepreneurs heal and grow. Matt also shares insights on the therapeutic potential of psilocybin, MDMA, and 5-MeO-DMT. Discover how psychedelics can enhance emotional availability, why set and setting are vital for safety, and how these tools are supporting veterans with PTSD.

Alaska Storm Forces Cruise Cancellations and Reroutes is today's lead story on Wednesday Travel and Cruise Industry Podcast, September 17, 2025 with Chillie Falls. Also this morning, Wonder of the Sea Returns After Onboard Brawl; Xcel Sea Trials; Pole Dancing Goes Wrong; Rent to Own at Sea; Texas Themed Entertainment from MSC; Carnival Crew Sentenced; Brazil to Auction Terminals; and lots more LIVE at 11 AM EDT. CLICK for video feed #wednesdaytravelandcruiseindustrypodcast #travelandcruiseindustrynews #podcast #cruisenews #travelnews #cruise #travel #chilliescruises #chilliefalls #whill_us Thanks for visiting my channel. NYTimes The Daily, the flagship NYT podcast with a massive audience. "Vacationing In The Time Of Covid" https://nyti.ms/3QuRwOS To access the Travel and Cruise Industry News Podcast; https://cms.megaphone.fm/channel/trav... or go to https://accessadventure.net/ To subscribe: http://bit.ly/chi-fal I appreciate super chats or any other donation to support my channel. For your convenience, please visit: https://paypal.me/chillie9264?locale.... Chillie's Cruise Schedule: https://www.accessadventure.net/chillies-trip-calendar/ For your mobility needs, contact me, Whill.inc/US, at (844) 699-4455 use SRN 11137 or call Scootaround at 1.888.441.7575. Use SRN 11137. YouTube: https://www.youtube.com/ChilliesCruises Facebook: https://www.facebook.com/chillie.falls X: https://x.com/ChillieFalls Learn more about your ad choices. Visit megaphone.fm/adchoices

En este episodio @MaleMalaver entrevista a      SANDRA ORNÉS VÁSQUEZ     . @sov2011 Urbanista, Msc. Gerencia Empresarial, Dra. Desarrollo Sostenible. Profesora Titular del Dpto. De Planificación Urbana de la Universidad Simón Bolívar, en Caracas. Tiene 29 años de experiencia profesional, atendiendo temas de planificación y gestión urbana, gestión integral de riesgo, desarrollo sostenible y competitividad de la ciudad. La Prof. Sandra nos habló acerca de los Indicadores de sostenibilidad para una gestión local parte 1  Los invitamos a escucharnos en vivo de lunes a viernes de 10am a 11am a través de Unión Radio 93.7 FM en Puerto La Cruz o por la web de Mundo UR https://mundour.com/index.php/anzoategui/ o por http://player.lorini.net/unionradio/puertolacruz/.

En este episodio @MaleMalaver entrevista a     SANDRA ORNÉS VÁSQUEZ    . @sov2011 Urbanista, Msc. Gerencia Empresarial, Dra. Desarrollo Sostenible. Profesora Titular del Dpto. De Planificación Urbana de la Universidad Simón Bolívar, en Caracas. Tiene 29 años de experiencia profesional, atendiendo temas de planificación y gestión urbana, gestión integral de riesgo, desarrollo sostenible y competitividad de la ciudad. La Prof. Sandra nos habló acerca de los Indicadores de sostenibilidad para una gestión local parte II Los invitamos a escucharnos en vivo de lunes a viernes de 10am a 11am a través de Unión Radio 93.7 FM en Puerto La Cruz o por la web de Mundo UR https://mundour.com/index.php/anzoategui/ o por http://player.lorini.net/unionradio/puertolacruz/.

In this episode of From the Helm, Grady Wulff sits down with Cynata Therapeutics (ASX:CYP) CEO, Kilian Kelly, to discuss the company's pioneering work in stem cell and regenerative medicine. Kilian shares insights on Cynata's mesenchymal stromal cell (MSC) platform, its unique “one donor, one time” approach, the path to commercialisation, and what investors can expect in the coming year.In this interview, Grady covers:(0:29) an introduction to Cynata and its core technology(1:05) the role and importance of mesenchymal stromal cells (MSCs)(2:06) how Cynata addresses the challenges facing MSC therapies(3:24) the game-changing “one donor, one time” model(8:09) Cynata's pipeline of assets in development(9:10) balance sheet strength and funding position(9:56) how Cynata compares with ASX peers(10:52) expected news flow over the next 12 months.This interview was recorded on Thursday, 11 September 2025.

En este episodio @MaleMalaver entrevista a    SANDRA ORNÉS VÁSQUEZ   . @sov2011 Urbanista, Msc. Gerencia Empresarial, Dra. Desarrollo Sostenible. Profesora Titular del Dpto. De Planificación Urbana de la Universidad Simón Bolívar, en Caracas. Tiene 29 años de experiencia profesional, atendiendo temas de planificación y gestión urbana, gestión integral de riesgo, desarrollo sostenible y competitividad de la ciudad. La Prof. Sandra nos habló acerca de los metodos de particacion Los invitamos a escucharnos en vivo de lunes a viernes de 10am a 11am a través de Unión Radio 93.7 FM en Puerto La Cruz o por la web de Mundo UR https://mundour.com/index.php/anzoategui/ o por http://player.lorini.net/unionradio/puertolacruz/.

Exploring the Efficacy of BMAC and ADSC Injections in Knee Osteoarthritis   Hosts: David Rosenblum,MD Overview: In this episode, we delve into a recent study published in the Indian Journal of Orthopaedics that compares the therapeutic efficacy of Bone Marrow Aspirate Concentrate (BMAC) and Adipose-Derived Stem Cells (ADSCs) for treating knee osteoarthritis (OA). The study aims to provide insights into the effectiveness of these regenerative treatments and their correlation with mesenchymal stem cell (MSC) cellularity. Key Points Discussed: Background on Osteoarthritis: Definition and impact of OA, particularly in older populations. Overview of traditional treatments and the shift towards regenerative medicine. Study Objectives: To compare the efficacy of BMAC and ADSC injections in symptomatic knee OA patients. To analyze MSC quantity and quality in harvested tissues from both sources. Methodology: Description of the study design involving 60 patients with knee OA. Details on patient demographics, injection protocols, and follow-up assessments (VAS, WOMAC, ROM). Results: Significant improvements in clinical scores for both BMAC and ADSC groups at 6 months. Discussion on the lack of significant correlation between MSC quantity and treatment efficacy. Insights into the success rates of MSC cultures from both bone marrow and adipose tissue. Conclusions: Both treatments demonstrated clinical improvements, with no substantial differences between them. BMAC showed higher MSC counts and faster recovery rates, but further research is needed to understand the underlying factors affecting efficacy. Implications for Clinical Practice: Considerations for clinicians when choosing between BMAC and ADSC treatments. Future directions for research in regenerative therapies for knee OA. References: Vitali, M., Ometti, M., Montalbano, F., et al. (2025). Bone Marrow Aspirate Concentrate (BMAC) Versus Adipose-Derived Stem Cells (ADSCs) Intra-articular Injection Therapeutic Efficacy in Knee OA Correlated to Their Mesenchymal Stem Cell (MSC) Cellularity: An Exploratory Comparative Pilot Study. Indian Journal of Orthopaedics. https://doi.org/10.1007/s43465-025-01525-z Listener Engagement: Join the conversation! Share your thoughts on BMAC and ADSC treatments for knee OA on social media using #JournalClubPodcast. Don't forget to subscribe for more discussions on the latest research in orthopaedics and regenerative medicine.

MSC's Dan Short on its new Alaska programme.

Tyler W. LeBaron, MSc, Ph.D., is the founder and executive director of the nonprofit Molecular Hydrogen Institute. With a background in biochemistry, physiology, and exercise science, he teaches exercise physiology and chemistry labs at Southern Utah University as an adjunct instructor. He interned at Nagoya University in Japan's Department of Neurogenetics, researching the molecular mechanisms of hydrogen gas on cell-signaling pathways. Tyler is a director of both the International Hydrogen Standards Association (IHSA) and the International Molecular Hydrogen Association (IMHA). He speaks at medical and academic conferences worldwide, collaborates with researchers globally, and works to advance the education and awareness of hydrogen as a therapeutic medical gas. Outside the lab, he trains in running and competes in arm wrestling. Alex Tarnava is a self-taught scientist, inventor, and author whose work bridges biomedical innovation, sovereign health, and philosophical disruption. He invented the world’s only open-cup molecular hydrogen tablet—a patented delivery system that has become the most studied and widely adopted form of hydrogen therapy, featured in over 21 published clinical trials. Alex has co-authored 17 peer-reviewed papers, with more in press and under review. He is also the co-inventor—alongside Tyler—of Inhale H₂, the first safe and effective hydrogen inhalation system. His leadership in the field led the Molecular Hydrogen Institute (MHI) to appoint him as the first chairman of its Research Committee. Full show notes: bengreenfieldlife.com/inhalehydrogen Episode Sponsors: LeelaQ: Not only do LeelaQ’s products neutralize EMFs, increase ATP production, optimize HRV, and improve blood flow, but they've been third-party proven to do so in placebo-controlled double-blind studies. Visit leelaq.com and use code BEN10 for 10% off. Gameday Men’s Health: Gameday Men's Health offers science-backed, physician-led men's health optimization with personalized protocols for testosterone, peptide therapy, ED treatment, and more—helping you perform at your best whether you're training hard or keeping up with life. Visit gamedaymenshealth.com/bengreenfield for a free testosterone test and consultation at a clinic near you. BEAM Minerals: If you want to up your mineral game, give BEAM Minerals a try. Go to beamminerals.com and use code BEN at checkout for 20% off your order. Thrive Market: Discover how Thrive Market delivers premium, clean-label groceries from top brands like Simple Mills and Primal Kitchen at up to 30% off retail prices, making healthy eating accessible without compromising your budget or values. Skip the junk without overspending—visit thrivemarket.com/ben for 30% off your first order plus a FREE $60 gift. BiOptimizers MassZymes: MassZymes is a powerful best-in-class enzyme supplement that improves digestion, reduces gas and bloating, and provides relief from constipation. Go to bioptimizers.com/ben and use code ben10 for 10% off your order. BON CHARGE: BON CHARGE is a holistic wellness brand with a wide range of products that naturally address the issues of modern life. Their products can help you sleep better, perform better, recover faster, balance hormones, reduce inflammation, and so much more. Go to boncharge.com/GREENFIELD and use coupon code GREENFIELD to save 15%.See omnystudio.com/listener for privacy information.

Vaughn Halliday, MSc, CFM, SFP, FMP, PMP, ProFM is Manager of Support Services and Facilities for the Central Bank of Trinidad & Tobago where he is a seasoned management executive with a specialized focus on facilities and project management, underpinned by a fervent commitment to sustainability. Mike Petrusky asks Vaughn why he believes that FM professionals need to lead with purpose, adapt with precision, and invest in people as much as they do in technology. They discuss the constant tension between short-term operational demands and long-term asset stewardship which often leads to deferred maintenance and reactive decision-making and Vaughn shares how the effective use of data from CMMS and BMS platforms is essential for driving strategic outcomes. He says that facility managers should move beyond a maintenance mindset and embrace FM as a strategic enabler of business outcomes by investing in training and credential programs at events like IFMA's World Workplace. The future of FM is already here, with AI, IoT, and smart systems reshaping how assets are managed, so Mike and Vaughn encourage and inspire you to be an Asset Champion in your organization! Connect with Vaughn on LinkedIn: https://www.linkedin.com/in/vaughn-halliday/ Learn more about IFMA: https://www.ifma.org/ Explore Eptura™: https://eptura.com/ Discover free resources and explore past interviews at: https://eptura.com/discover-more/podcasts/asset-champion/ Connect with Mike on LinkedIn: https://www.linkedin.com/in/mikepetrusky/  

Can this Hypnotherapy Help You Fall Asleep Tonight?Feeling anxious about going to work tomorrow?Accelerated Hypnotherapy: Release Anxiety & Experience Deep SleepWelcome to Accelerated Hypnotherapy, your guided session to gently release anxiety and immerse yourself into a deep and peaceful sleep. Settle in for a session of deep relaxation with this guided deep sleep hypnosis. This session blends theta brain wave calming music with gentle prompts, providing anxiety relief and encourages a peaceful sleep meditation using hypnosis for insomnia. Drift away with this relaxing music.

In our first episode of On Brand: Taylor's Version, we're joined by Sinéad O'Sullivan — aerospace engineer turned business strategist, former head of Strategy at Harvard Business School, professor, and co-founder of a global investment fund. She's advised everyone from NASA to prime ministers … and she also happens to be in the top 0.01% of Taylor Swift fans worldwide. Her new book, Good Ideas and Power Moves: Business Lessons from Taylor Swift, hits shelves this week — and she's here to share why Taylor isn't just a pop star, but one of the sharpest strategists of our time. What You'll Learn in This Episode Why “doing strategy” is more than PowerPoints and wish lists How Taylor Swift creates interlinked universes across her albums What it means to be anti-fragile and thrive in chaotic environments How storytelling can be leveraged as a business strategy Why Taylor Swift is her own product and outperforms traditional companies Episode Chapters (00:00) Intro (01:00) Getting Started with Taylor's Version (01:35) Reputation Era Story Prompt and Misunderstandings (03:40) Doing Strategy the Taylor Way (08:10) Building Worlds Not Products (12:30) Lessons for Brands and Community (17:50) Fearless Era Story Prompt and Courage (24:20) Anti-Fragile Moves and Thriving in Chaos (28:10) Timing, Reverse Acquisitions, and Big Picture Strategy (38:30) Where to Connect with Sinéad About Sinéad O'Sullivan Sinéad O'Sullivan is an aerospace engineer turned business strategist, former head of strategy at Harvard Business School, professor, writer, and co-founder of a global investment fund. She has advised organizations from NASA to prime ministers and is the author of Good Ideas and Power Moves: Business Lessons from Taylor Swift. O'Sullivan has a BA in engineering, an MSc in finance, and a PhD in strategy. What Brand Has Made Sinéad Smile Recently? Sinéad shared that she's been smiling at the creative universe built around Barbie. From specialty cars to Airbnbs, the way Barbie has expanded into a full cultural ecosystem reminded her of the worlds Taylor Swift builds with her albums—demonstrating creativity, collaboration, and clever brand storytelling. Resources & Links Connect with Sinéad on LinkedIn. Sinéad's website. Sinéad's Substack. Sinéad's new book, Good Ideas and Power Moves: Ten Lessons for Success from Taylor Swift. Listen & Support the Show Watch or listen on Apple Podcasts, Spotify, YouTube, Amazon/Audible, TuneIn, and iHeart. Rate and review on Apple Podcasts and Spotify to help others find the show. Share this episode — email a friend or colleague this episode. Sign up for my free Story Strategies newsletter for branding and storytelling tips. On Brand is a part of the Marketing Podcast Network. Until next week, I'll see you on the Internet! Learn more about your ad choices. Visit megaphone.fm/adchoices

We love to hear from our listeners. Send us a message.On episode 111 of Cell & Gene: The Podcast, Host Erin Harris talks to Ernexa Therapeutics' President and CEO, Sanjeev Luther, about how the company is advancing cell therapy innovation for cancer and autoimmune disease through engineered induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs). Luther shares how Ernexa's synthetic, standardized, off-the-shelf iMSCs are designed to overcome historic hurdles in MSC therapy, including variability, scalability, and manufacturing complexity, by leveraging master cell banks, precise gene editing, and novel product engineering. He also shares insights into the process of developing pro- and anti-inflammatory iMSCs for oncology and autoimmunity.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

In this episode of The Food Professor Podcast, hosts Michael LeBlanc and Dr. Sylvain Charlebois tackle the latest headlines shaping Canada's food and retail landscape before welcoming back a dynamic entrepreneur reshaping the seafood category.The conversation begins with a heated national debate: should Canada eliminate the Temporary Foreign Worker Program? Sylvain outlines the program's critical role in agriculture, agri-food processing, and restaurants, weighing the Conservative proposal to phase it out against industry concerns. He highlights the tension between labour shortages in rural communities and youth unemployment, noting how food service has become “addicted” to low-wage labour. Michael points to staggering statistics—40,000 people applied for seasonal jobs at the Canadian National Exhibition—illustrating the urgency of balancing wages, job availability, and immigration.From labour, the hosts turn to politics and trade. They unpack Quebec's cabinet shuffle and the departure of one of the province's longest-serving agriculture ministers, praising his role in championing Canada's Grocery Code of Conduct. Sylvain also reveals how Cody Blois, now Secretary of State to Agriculture in the Prime Minister's Office, may wield more influence over ag policy than the minister himself. There's cautious optimism with both China and India as Canada reopens diplomatic channels, while debates over canola's contribution to GDP spark discussion about food security, branding, and farmer uncertainty.The news segment also dives into consumer behaviour trends: Tim Hortons' launch of a protein-fortified latte (with Starbucks poised to follow), the surging popularity of food delivery apps despite their impact on food literacy and household budgets, and the mixed fortunes of Canadian farmers—livestock producers are enjoying high returns, while grain and dairy producers face challenges. Finally, Michael and Sylvain discuss Cracker Barrel's failed brand refresh, underlining the importance of innovation that resonates with consumers.The second half features a spirited interview with Charlotte Langley, Founder of Nice Cans and CEO of Langley Foods. A chef, ocean steward, and veteran food entrepreneur, Charlotte shares how her cheekily named canned seafood brand is making sustainability delicious. She explains how pushing for MSC certification in Portugal helped transform the entire sardine fishery, elevating sustainability standards across 21 operations. Charlotte also details her collaborations—like a World Oceans Day partnership with Cheekbone Beauty—and the creative process behind launching new products that are both innovative and scalable.Special listener discount: Use code DELISHFISH for 20% off

Lauren Juliff is Climate and Sustainability Product Lead and Head of UK Institutional at Storebrand Asset Management UK. Her educational background is in science and she has a MSc in Climate Change: Environment, Science and Policy. We start our conversation with Lauren's background and a passion for dance that she has carried throughout her life. We mention this as a reminder to take time to nurture health, and joy, even in the small moments. Moving then to her professional career we discuss the evolution of climate and sustainability products, and how she was motivated to pursue a post graduate degree in the area of climate change policy. We discuss then how this enriched her approach to product development and solution building and look at the outlook for this and similar strategies.  Why we made this? Lauren is a passionate industry member with a unique blend of an academic background in Climate Change, Environment, Science and Policy as well as an understanding as to how sustainability products are fashioned and delivered.  Why we think you may like it? A growing body of investors is interested in climate and sustainability products, and this podcast provides insights on product positioning, the evolving nature of client demand  With thanks to Baillie Gifford for sponsoring Series 4 of 2025. Baillie Gifford is a long-term investment manager, dedicated to discovering the innovations and changemakers that deliver exceptional growth opportunities for its clients.

We discuss the May 16 FDA approval of the first blood test to diagnose Alzheimer disease. This landmark approval marks a significant shift in how Alzheimer disease is identified, moving away from more traditional methods or invasive methods. Our guests, Howard Fillit, the Alzheimer's Drug Discovery Foundation, and Anthony “Nino” Sireci, MD, MSc, Eli Lilly and Company, help us understand this “huge accomplishment" and how it may be able to transform the diagnostic landscape from one of nihilism to one of hope and early intervention.

Want the latest news, analysis, and price indices from power markets around the globe - delivered to your inbox, every week?Sign up for the Weekly Dispatch - Modo Energy's unmissable newsletter.As renewables take a larger share of the power mix, the need for flexibility in electricity markets has never been greater. But while the technology exists. From batteries and demand response to interconnectors the challenge lies in creating the right market structures and incentives to bring it all together.Today's power markets were designed around centralised fossil generation. For flexibility to scale, they must evolve, ensuring that short-term trading, ancillary services, and long-term contracts all work in harmony. Without that, renewable integration will stall, and the cost of balancing the grid will rise.In this episode of Transmission, Quentin is joined by Rasmus Rode Mosbæk to explore the future of energy trading and flexibility markets. They discuss how market design can enable faster renewable integration, why transparency and liquidity matter, and what lessons can be drawn from other European systems. Over the course of the conversation, they discuss:Why flexibility is the missing piece in renewable integration.How market design shapes investment and innovation in storage.The growing role of short-term trading in balancing the grid.Lessons from European power markets on flexibility and liquidity.What's needed to unlock the full potential of demand-side response.About our guestRasmus Rode Mosbæk is the CEO and Founder of Hybrid Greentech, a Danish software company specialising in intelligent energy storage solutions. With an MSc and PhD in energy systems, Rasmus combines deep technical expertise with commercial insight to deliver smarter ways of integrating renewables into the grid. At Hybrid Greentech, he leads the development of HERA, an AI-powered platform that optimises virtual power plants and battery storage, helping asset owners maximise revenues, extend asset lifetimes, and strengthen grid stability. For more information on Hybrid Greentech, head to their website.About Modo EnergyModo Energy helps the owners, operators, builders, and financiers of battery energy storage solutions understand the market - and make the most out of their assets.All of our podcasts are available to watch or listen to on the Modo Energy site. To keep up with all of our latest updates, research, analysis, videos, podcasts, data visualizations, live events, and more, follow us on LinkedIn. Check out The Energy Academy, our bite-sized video series breaking down how power markets work.

Want the latest news, analysis, and price indices from power markets around the globe - delivered to your inbox, every week?Sign up for the Weekly Dispatch - Modo Energy's unmissable newsletter.As renewables take a larger share of the power mix, the need for flexibility in electricity markets has never been greater. But while the technology exists. From batteries and demand response to interconnectors the challenge lies in creating the right market structures and incentives to bring it all together.Today's power markets were designed around centralised fossil generation. For flexibility to scale, they must evolve, ensuring that short-term trading, ancillary services, and long-term contracts all work in harmony. Without that, renewable integration will stall, and the cost of balancing the grid will rise.In this episode of Transmission, Quentin is joined by Rasmus Rode Mosbæk to explore the future of energy trading and flexibility markets. They discuss how market design can enable faster renewable integration, why transparency and liquidity matter, and what lessons can be drawn from other European systems. Over the course of the conversation, they discuss:Why flexibility is the missing piece in renewable integration.How market design shapes investment and innovation in storage.The growing role of short-term trading in balancing the grid.Lessons from European power markets on flexibility and liquidity.What's needed to unlock the full potential of demand-side response.About our guestRasmus Rode Mosbæk is the CEO and Founder of Hybrid Greentech, a Danish software company specialising in intelligent energy storage solutions. With an MSc and PhD in energy systems, Rasmus combines deep technical expertise with commercial insight to deliver smarter ways of integrating renewables into the grid. At Hybrid Greentech, he leads the development of HERA, an AI-powered platform that optimises virtual power plants and battery storage, helping asset owners maximise revenues, extend asset lifetimes, and strengthen grid stability. For more information on Hybrid Greentech, head to their website.About Modo EnergyModo Energy helps the owners, operators, builders, and financiers of battery energy storage solutions understand the market - and make the most out of their assets.All of our podcasts are available to watch or listen to on the Modo Energy site. To keep up with all of our latest updates, research, analysis, videos, podcasts, data visualizations, live events, and more, follow us on LinkedIn. Check out The Energy Academy, our bite-sized video series breaking down how power markets work.

In this episode of Advanced Practice Weekly, host Ajay Bhatt takes us inside the world of advanced practice in cancer care at the Royal Marsden Hospital. He's joined by two outstanding professionals Danielle Pinnock and Victoria Sinnett. They offer powerful insights into how advanced practice is shaping patient care, education, and innovation in oncology. Danielle Pinnock, the Coordinating Education Supervisor in Advanced Practice, shares how she supports supervisors across the Trust and helps embed quality education into cancer care pathways. She explains how the Royal Marsden School's specialised MSc programme is developing skilled practitioners who make complex clinical decisions, lead services, and transform care delivery. Later, Victoria Sinnett, Consultant Breast Radiographer, reflects on her career journey and how advanced practice has enabled radiographers like her to take on expanded clinical roles, providing continuity and compassionate care to patients. From biopsies to presenting in MDTs and pioneering new surgical technology, Victoria's work is a testament to how advanced practice is redefining the future of oncology services. This episode highlights how advanced practitioners are meeting rising service demands, contributing to innovation, and driving change in cancer care, one patient at a time. A full transcript of this episode is available on our website - https://www.england.nhs.uk/long-read/podcast-advanced-practice-weekly-20/ Please get in touch if you have any questions regarding this episode - england.acpenquirieslondon@nhs.net

Felix Frenzel is the Founding Partner of Kadan Capital, a Singapore-headquartered early-stage venture capital firm backing category-defining startups across Southeast Asia and beyond. At Kadan, he focuses on high-impact companies in fintech and artificial intelligence, targeting ventures with strong early traction and potential for rapid scale.Before co-founding Kadan Capital, Felix built his expertise across investment management and strategy consulting. He was an Investment Manager at Antler, a leading global early-stage VC platform, and a strategy consultant at Bain & Company, where he advised top-tier clients on transformative growth strategies. Earlier in his career, he gained experience in public equity investing, adding depth to his financial acumen.Felix's passion for investing runs deep. At just sixteen, he launched a small fund focused on European equities—a first step that reflects both his entrepreneurial drive and early fascination with capital markets.He holds an MBA from INSEAD, an MSc in International Finance from HEC Paris, and a BSc in Economics from the University of Bonn.LinkedIn: https://www.linkedin.com/in/felixfrenzel/

durée : 00:04:09 - Le Fil éco - De la mer aux médias, les armateurs MSC, Maersk, CMA CGM et COSCO étendent leur empire. Arnaud Orain s'interroge : vers un capitalisme piloté par les océans ? - réalisation : Nicolas Berger

In this special episode, the creators of SAMR, TPACK, Triple E, SETI, and GenAI-U reflect on how their views of AI in education have evolved since the launch of ChatGPT in November 2022. They share hard lessons learned and insights gleaned, offering a candid look at the ups and downs in their journey through periods of awe, skepticism, and embracing AI's potential. As they prepare to head back to school, they discuss their personal AI use, how their own kids are using AI, and their updated thinking on cheating prevention strategies. The group expands the lens to examine tech companies' AI promises, why Grammarly's new feature is shaking up grading, and how AI is impacting our relationships on many levels. They conclude by sharing how they plan to approach AI differently as they head back to school this term. Follow on X: @CFKurban @hcrompton @lkolb @punyamishra @jonHarper70bd @bamradionetwork Dr. Punya Mishra (punyamishra.com) is the Associate Dean of Scholarship and Innovation at the Mary Lou Fulton Teachers College at Arizona State University. He has an undergraduate degree in Electrical Engineering, two Master's degrees in Visual Communication and Mass Communications, and a Ph.D. in Educational psychology. He co-developed the TPACK framework, described as “the most significant advancement in technology integration in the past 25 years.” Dr. Caroline Fell Kurban is the advisor to the Rector at MEF University. She was the founding Director of the Center of Research and Best Practices for Learning and Teaching (CELT) at MEF University and teaches in the Faculty of Education. She holds a BSc in Geology, an MSc in TESOL, an MA in Technology and Learning Design, and a PhD in Applied Linguistics. Fell Kurban is currently the head of the Global Terminology Project and the creator of the GenAI-U technology integration framework. Dr. Liz Kolb is a clinical professor at the University of Michigan and the author of several books, including Cell Phones in the Classroom and Help Your Child Learn with Cell Phones and Web 2.0. Kolb has been a featured and keynote speaker at conferences throughout the U.S. and Canada. She created the Triple E Framework for effective teaching with digital technologies and blogs at cellphonesinlearning.com. Dr. Puentedura is the Founder and President of Hippasus, a consulting practice focusing on transformative applications of information technologies to education. He has implemented these approaches for over thirty years at various K-20 institutions and health and arts organizations. He is the creator of the SAMR model for selecting, using, and evaluating technology in education and has guided multiple projects worldwide. Dr. Helen Crompton is the Executive Director of the Research Institute for Digital Innovation in Learning at ODUGlobal and Professor of Instructional Technology at Old Dominion University. Dr. Crompton earned her Ph.D. in educational technology and mathematics education from the University of North Carolina at Chapel ill. Dr. Crompton is recognized for her outstanding contributions and is on Stanford's esteemed list of the world's Top 2% of Scientists. She is the creator of the SETI framework. She frequently serves as a consultant for various governments and bilateral and multilateral organizations, such as the United Nations and the World Bank, on driving meaningful change in educational technology.

Jack Waverley is a senior lecturer in marketing at the University of Manchester. He uses marketing and consumer research to protect and promote the interests of all animals, including humans. Jack teaches on a range of BSc and MSc courses in the Fashion, Business, and Technology (FBT) group. He also supervises a number of PhD and dissertation students. He is an academic expert member of the Academy of Marketing and a member of the Vegan Society's Research Advisory Committee.In Sentientist Conversations we talk about the most important questions: “what's real?”, “who matters?” and "how can we make a better world?"Sentientism answers those questions with "evidence, reason & compassion for all sentient beings." The video of our conversation is ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here on YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.00:00 Clips00:52 Welcome- Jack's talk at VARC 2025- "The VARC conference is like being in the future...where we want to get to... it really does feel like you've jumped forward 10 years"02:49 Jack's Intro- A marketing consumer researcher... focusing both onconsumption of animals and consumption for animals- "Markets as a system of morals... material objects moving around... infrastructures"- "How we move from one system to another"- The AI question "I very much adopt a sentiocentric or Sentientist perspective"- "The reason I'm concerned about animals is because they are sentient"- "If AI were to become sentient... then of course they would fall within... my moral circle"- "Most people think about 'what can AI do for me... for humans?... How does AI affect humanity?'"- "I'm much more interested in 'what can we do for AI?'... our responsibilities for AI... how can AI help post-humanity, more than humanity, all sentient beings."- "I've ended up in this... very anthropocentric tradition... marketing and consumer research... but bringing in animals and bringing in AI"- A new field of #SentientistMarketing ?05:14 What's Real- Growing up in "a nominally Christian household... but we never went to church... more agnostic"- "There was never an explicit framework of... this is why these things are good or bad"- A liberal, progressive upbringing "live and let live"- "It wasn't quite a blank slate [re: moral thinking] but it was as close as you probably get"- "Broadly naturalistic is my baseline... interested in biology, chemistry, physics, mathematics... scientific ways of approaching the world"- "I didn't really go out looking for any kind of revelation... [or] any strict rules... [or] some sort of authority figure"- "I didn't mind other people having religion but for me it just didn't make sense... I was naturalistic"31:44 What and Who Matters?35:50 A Better World?01:21:40 Follow Jack:- Jack at Manchester University- Jack on LinkedIn (please get in touch)And more... full show notes at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sentientism.info⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Sentientism is “Evidence, reason & compassion for all sentient beings.” More at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sentientism.info⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Join our⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠"I'm a Sentientist" wall⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ via⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ this simple form⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Everyone, Sentientist or not, is welcome in our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠groups⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. The biggest so far is ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here on FaceBook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Come join us there!

Chorea describes involuntary movements that are random, abrupt, and unpredictable, flowing from one body part to another. The most common cause of genetic chorea in adults is Huntington disease, which requires comprehensive, multidisciplinary care as well as support for care partners, who may themselves be diagnosed with the disease. In this episode, Aaron Berkowitz, MD, PhD FAAN speaks with Kathryn P. L. Moore, MD, MSc, author of the article “Huntington Disease and Chorea” in the Continuum® August 2025 Movement Disorders issue. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology at the University of California San Francisco in the Department of Neurology in San Francisco, California. Dr. Moore is an assistant professor and director of the Parkinson's Disease and Movement Disorders Fellowship in the department of neurology at Duke University in Durham, North Carolina. Additional Resources Read the article: Huntington Disease and Chorea Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz Guest: @KatiePMooreMD Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Berkowitz: This is Dr Aaron Berkowitz with Continuum Audio, and today I'm interviewing Dr Kathryn Moore about her article on diagnosis and management of Huntington disease and chorea, which appears in the August 2025 Continuum issue on movement disorders. Welcome to the podcast, Dr Moore. Could you please introduce yourself to our audience? Dr Moore: Yeah, thank you so much. I'm so excited to be here. I'm Dr Moore. I'm an assistant professor of neurology at Duke University, where I work as a movement disorder specialist. I run our fellowship there and help with our residency program as well. So, I'm excited to speak with our listeners about chorea today. Dr Berkowitz: Fantastic. And we're excited to talk to you about chorea. So, as a general neurologist myself, I only see chorea pretty rarely compared to other movement disorders like tremor, myoclonus, maybe the occasional tic disorder. And like anything I don't see very often, I always have to look up the differential diagnosis and how to evaluate a patient with chorea. So, I was so glad to read your article. And next time I see a patient with chorea, I know I'll be referring to your article as a great reference to have a framework for how to approach it. I hope our readers will look at all these helpful tables on differential diagnosis based on distribution of chorea in the body, potential etiologies, time course of onset and evolution, associated drug-induced causes, what tests to send. So, I highly recommend our listeners read the article. Keep those tables handy for when a patient comes in with chorea. I'm excited to pick your brain about some of these topics today. First, how do you go about distinguishing chorea from other hyperkinetic movement disorders when you see a patient that you think might have chorea? Dr Moore: One of the wonderful things about being a movement disorder specialist is we spend a lot of time looking at movements and training our brain to make these distinctions. The things that I would be looking out for chorea is involuntary, uncontrolled movements that appear to be brief and flowing from one part of the body to another. So, if you can watch a patient and predict what movements they're going to do, this probably isn't chorea. And it should be flowing from one part of the body to another. So, not staying just in one part of the body or having sustained movements. It can be difficult to distinguish between a tic or dystonia or myoclonus. Those things tend to be more predictable and repetitive than the chorea, which tends to be really random and can look like dancing. Dr Berkowitz: That's very helpful. So, once you've decided the patient has chorea, what's your framework for thinking about the differential diagnosis of the cause of the patient's chorea? Dr Moore: Well, that could be really challenging. The differential for chorea is very broad, and so the two things that I tend to use are age of the patient and acuity of onset. And so, if you're thinking about acute onset of chorea, you're really looking at a structural lesion like a stroke or a systemic issue like infection, hyperglycemia, etc. Where a gradually progressive chorea tends to be genetic in nature. When you're thinking about the difference between a child and an adult, the most common cause of chorea in a child is Sydenham's chorea. And actually, the most common cause of chorea that I tend to see is Parkinson's disease medication. So, if anybody's seen dyskinesia in Parkinson's disease, you've seen chorea. But it's those two things that I'm using, the age of the patient and the acuity. Somewhere in the middle, though---so, if you have subacute onset of chorea---it's important to remember to think about autoimmune conditions or paraneoplastic conditions because these are treatable. Dr Berkowitz: That's very helpful. So, like in any chief concern in neurology, we're using the context like the age and then the time course. And then a number of other helpful points in your article about the distribution of chorea in the body. Any comments you'd like to make about- we have this very helpful table that I thought was very interesting. So, you really get deep into the nuances of chorea and the movement disorder specialist expert level. Are there any aspects of parts of the body affected by chorea or distribution of chorea across the body that help you hone your differential diagnosis? Dr Moore: Certainly. I think where the chorea is located in the body can be helpful, but not as helpful as other conditions where you're localizing a lesion or that sort of thing. Because you can have a systemic cause of chorea that causes a hemichorea; that you can have hyperglycemia causing a hemichorea, or even Sydenham's chorea being a hemichorea. But things that we think about, if the forehead is involved, I would think about Huntington's disease, although this is not pathognomonic. And if it's involving the face or the mouth, you can think about neuroacanthocytosis or, more commonly, tardive dyskinesia. Hemichorea would make me think about some of those systemic issues like hyperglycemia, Sydenham's chorea, those sorts of things, but I would rely more on the historical context and the acuity of presentation than the distribution itself. Dr Berkowitz: Got it. That's very helpful. So those can be helpful features, but not sort of specific for any particular condition. Dr Moore: Exactly. Dr Berkowitz: Yeah, I often see forehead chorea mentioned as sort of specific to Huntington's disease. Since I don't see much Huntington's disease myself, what does forehead chorea look like? What is the forehead doing? How do you recognize that there is chorea of the forehead? It's just sort of hard for me to imagine what it would look like. Dr Moore: It's really tricky. I think seeing the eyebrows go up and down or the brows furrow in an unpredictable way is really what we're looking for. And that can be hard if you're having a conversation. My forehead is certainly animated as we're talking about one of my favorite topics here. One of the tricks that I use with the fellows is to observe the forehead from the side, and there you can see the undulation of the forehead muscles. And that can be helpful as you're looking for these things. I think where it's most helpful to use the forehead is if you're trying to determine if someone with a psychiatric history has tardive dyskinesia or Huntington's disease, because there can be quite a lot of overlap there. And unfortunately, patients can have both conditions. And so, using the forehead movement can be helpful to maybe direct further testing for Huntington's disease. Dr Berkowitz: Oh, wow, that's a very helpful pearl. So, if you see, sort of, diffuse chorea throughout the body and the forehead is involved, to my understanding it may be less specific. But in the context of wondering, is the neuropsychiatric condition and movement disorder related by an underlying cause in the case of seeing orofacial dyskinesias, is the relationship a drug having caused a tardive dyskinesia or is the whole underlying process Huntington's, the absence of forehead might push you a little more towards tardive dyskinesia, presuming there is an appropriate implicated drug and the presence of forehead chorea would really clue you in more to Huntington's. Did I understand that pearl? Dr Moore: That's exactly right, and I'm glad you brought up the point about making sure, if you're considering tardive dyskinesia, that there has been an appropriate drug exposure. Because without that you can't make that diagnosis. Dr Berkowitz: That's a very helpful and interesting pearl, looking at the forehead from the side. That is a movement disorders pearl for sure. Sort of not just looking at the forehead from one angle and trying to figure out what it's doing, but going to look at the patient in profile and trying to sort it out. I love that. Okay. So, based on the differential diagnosis you would have crafted based on whether this is sort of acute, subacute, chronic, the age of the patient, whether it's unilateral, bilateral, which parts of the body. How do you go about the initial evaluation in terms of laboratory testing, imaging, etc.? Dr Moore: Well, certainly in an acute-onset patient, you're going to get a number of labs---and that's listed out for you in the paper---and consider imaging as well, looking for an infarct. One thing our learners will know is that sort of the typical answer to what's the infarct causing hemichorea would be the subthalamic nucleus. But really, those infarcts can be almost anywhere. There are case reports for infarcts in a wide variety of places in the brain leading to hemichorea. So, I think some general blood work and an MRI of the brain is a good place to start. For someone who has a more chronic course of the development of chorea, there are certain labs that I would get---and an MRI, because if you get an MRI and there's heavy metal deposition or other disease, structurally, that indicates a certain condition, that can help you pretty considerably. But otherwise, I'm looking for inflammatory markers, heavy metals, HIV, some general other things that are outlined, to help make sure that I'm not missing something that's treatable before I go down the route of genetic testing. And we may talk about this in a little bit, but if you start out with genetic testing and then you sort of have to back up and do more systemic testing, that can be very disjointed when it comes to good patient care. Dr Berkowitz: That's very helpful. So yeah, if it's acute, obviously this is the most straightforward scenario, acute and unilateral. We're imagining something lesional, as you said, either a stroke or---not sort of sudden, but fast, but not sudden---you might think of another structural lesion. Toxoplasmosis, right, has an affinity for the basal ganglia if you were seeing this in a patient who is immunocompromised. But in a case that, probably as you alluded to, sort of what we would see most commonly in practice, those still relatively rare, sort of subacute to chronic symmetric chorea. There's a long list of tests that are recommended. In your article and in other texts, I've read lupus testing, anti-phospholipid antibodies… but the list is long. I'll refer readers to your article. Out of curiosity as a specialist, how often do you see any of these labs come back revealing any underlying diagnosis in a patient who's otherwise healthy and just has developed chorea and comes to you with that chief concern? I feel like I've sent that mega-workup a few times; I'm obviously a general neurologist, but not nearly as many times as you have been. It's- I can't remember a time where something has come up, maybe an ANA one to forty or something like this that we don't think is relevant. But in your practice, how often do you end up finding a reversible cause in the laboratory testing versus ending up starting to go down the genetic testing route, which we'll talk about in a moment? Dr Moore: It's not common, but it is important that we capture these things. Because for a lot of those laboratory tests, there are treatments that are available, or other health implications if those come back positive. So, the case I think of is a polycythemia vera patient who had diffused subacute onset chorea and was able to be treated, was temporarily managed with medication for her chorea, and as her PV improved, she was able to come off those medications. As I was alluding to before---and I'm sure we'll talk about genetic testing---if you test for HD and it's negative, do you go down the route of additional expensive genetic testing, or do you then circle back and go, oops, I missed this treatable condition? As we talk about genetic testing as well, getting HD testing is a pretty involved process. And so, we want to make sure we are checking all those boxes before we move forward. So, it's not common, but we do catch some treatable conditions, and that's really important not to miss. Dr Berkowitz: That's very interesting. So, you diagnosed that polycythemia vera by blood smear, is that how you make the diagnosis? Dr Moore: Yes. Dr Berkowitz: And is that a once-in-a-career-so-far type of thing, or does that happen time to time? Dr Moore: For me, that's a once-so-far, but I don't doubt that I'll see it again. Dr Berkowitz: Great. And how about lupus and some of these other things we look for in the absence of other systemic features? Have you picked up any of these or heard of colleagues picking up something on laboratory testing? They said, oh, this patient came in for a referral for genetic testing, negative Huntington's disease. And good news, we found polycythemia vera; good news, we found undiagnosed lupus and we reversed it. I'm just curious, epidemiologically, seeing these long lists and not having the subspecialty practice that you do, how often you find a reversible cause like we do for neuropathy all the time, right? Oh, it's diabetes, it's B12---maybe not reversible, but preventing progression---or reversible dementia work up. You get so excited when you find low B12 and you replete the patient's B12, and they get better when they had been concerned they were developing an irreversible condition. How often does one in your subspecialty find a reversible cause on that initial mega-lab screen? Dr Moore: I think it's really uncommon, and maybe the folks that do are caught by someone else that never make it to Huntington's clinic, but I don't tend to see those cases. There are, of course, case reports and well-described in the literature about lupus and movement disorders and things of that nature, but that doesn't come to our clinic on a regular basis for sure. Dr Berkowitz: Got it. That's helpful to hear. Well, we've alluded to genetic testing a number of times now, so let's go ahead and talk about it. A lot of your article focuses on Huntington disease, and I was thinking about---in the course of our medical training in medical school, and then neurology residency, for those of us who don't become movement disorder experts like yourself---we learn a lot about Huntington disease. That's sort of the disease that causes chorea, until we later learned there are a whole number of diseases, not just the reversible causes we've been talking about, but a number of genetic diseases which you expertly reviewing your article. So, what are some of the red flags that suggest to you that a patient with chronically progressive chorea---and whom you're concerned for Huntington's or another genetic cause---what are some things you notice about the history, about the exam, the symptoms, the signs, the syndrome, that suggest to you that, actually, this one looks like it might not turn out to be HD. I think this patient might have something else. And as you have alluded to, how do you approach this? Do you send HD testing, wait for it to come back, and then go forward? Are there genetic panels for certain genetic causes of chorea? Do you skip just a whole exome sequencing, or will you miss some of the trinucleotide repeat conditions? How do you approach this in practice? Dr Moore: I'll try to tackle all that. One thing I will say is that a lot of patients with chorea, regardless of the cause, can look very similar to one another. So, if you're looking at chronic onset chorea, perhaps with some neuropsychiatric features, I'm going to most often think about HD because that's the most common cause. Certainly, as we mentioned before, if there's a lot of tongue protrusion, I would think about the acanthocytic conditions, neurocanthocytosis and McCloud syndrome. But generally in those conditions, we're looking at HD as the most likely cause. Certainly, if there is epilepsy or some other syndromic types of things going on, I may think more broadly. But it's important to know that while HD, as you mentioned, is the cause of chorea, many of our patients will have parkinsonism, tics, dystonia, a whole host of other movement phenomenologies. So, that wouldn't dissuade me from thinking about HD. When we think about the kind of patients that you're describing, upwards of 95% of those people will have Huntington's disease. And the process for genetic testing is fairly involved. The Huntington's Disease Society of America has organized a set of recommendations for providers to go about the process of genetic testing in a safe and supportive way for patients and their families. And so that's referred to in the article because it really is important and was devised by patients and families that are affected by this disease. And so, when we're thinking about genetic testing for HD, if I reveal that you have HD, this potentially affects your children and your parents and your siblings. You can have a lot of implications for the lives and health and finances of your family members. We also know that there is high suicidality in patients with HD, in patients who are at risk for HD; and there's even a higher risk of suicidality in patients who are at risk but test negative for HD. So, we do recommend a supportive environment for these patients and their families. And so, for presymptomatic patients or patients who are at risk and don't have chorea, this involves making sure we have, sort of, our ducks in a row, as it were, when we think about life insurance, and, do you have somebody supportive to be with you through this journey of genetic testing, no matter what the results are? So, oftentimes I'll say to folks, you know, there's this 20-page policy that I encourage you to look at, but there are Huntington's Disease Centers of Excellence across the country that are happy to help you with that process, to make sure that the patients are well supported. This is an individual genetic test because, as you mentioned, it is a CAG repeat disorder. And unfortunately, there is no chorea panel. So, if an HD test comes back negative, what we'll do then is think about what's called the HD phenocopies. As I mentioned before, some of these patients who look like they have HD will have a negative HD test. And so, what do you do then? Well, there's a handful of phenocopies---so, other genetic mutations that cause a very similar presentation. And so, we try to be smart, since there's not a panel, we try to be smart about how we choose which test to do next. So, for instance, there's a condition called DRPLA that is present in an African-American family here in my area, in North Carolina, as well as in Japan. And so, if someone comes from those backgrounds, we may decide that that's the next test that we're going to do. If they are white European descent, we may consider a different genetic test; or if they're sub-Saharan African, we may choose a different one from that. However, even if you do a really thorough job, all those blood tests, all those genetic tests, you will occasionally get patients that you can't find a diagnosis for. And so, it's important to know even when you do a good job, you may still not find the answer. And so, I think trying to do things with this complex of the presentation in a systematic way for yourself so you're not missing something. So, going back to our answer about, how do I look at lupus and polycythemia vera and all of that, to think about it in a systematic way. That when you get to the end and you say, well, I don't have an answer, you know you've tried. Dr Berkowitz: That's very helpful to hear your approach to these challenging scenarios, and also how to approach the potential challenging diagnosis for patients and their families getting this diagnosis, particularly in the presymptomatic phase. And your article touches on this with a lot of nuance and thoughtfulness. So, I encourage our listeners to have a read of that section as well. So, last here, just briefly in our final moments, you discuss in your article the various symptomatic treatments for chorea. We won't have time to go into all the details of all the many treatments you discussed, but just briefly, how do you decide which medication to start in an individual patient with chorea for symptomatic management? What are some of the considerations related to the underlying condition, potential side effect profiles of the particular medications, or any other considerations just broadly, generally, as you think about choosing one of the many medications that can be used to treat chorea? Dr Moore: Certainly. So, there is a group of FDA-approved medications, VMAT2 inhibitors, that we can choose from, or the off-label use of neuroleptics. And so, there's a lot of things that go into that. Some of that is insurance and cost and that sort of thing, and that can play a role. Others are side effects. So, for the VMAT2 inhibitors, they all do have a black box warning from the FDA about suicidality. And so, if a patient does struggle with mental health, has a history of suicidality, psychiatric admissions for that sort of thing, then I would be more cautious about using that medication. All patients are counseled about that, as are their families, to help us give them good support. So, the neuroleptics do not tend to have that side effect and can help with mood as well as the chorea and can be helpful in that way. And some of them, of course, will have beneficial side effects. So, olanzapine may help with appetite, which can be important in this disease. So, the big considerations would be the black box warning and suicidality, as well as, are we trying to just treat chorea or are we treating chorea and neuropsychiatric issues? Dr Berkowitz: Fantastic. Thank you for that overview. And again, for our listeners, there's a lot more detail about all of these medications, how they work, how they're used in different patient populations, their side effects, etc, to be reviewed in your excellent article. Again, today, I've been interviewing Dr Kathryn Moore about her article on diagnosis and management of Huntington's disease in chorea, which appears in the August 2025 Continuum issue on movement disorders. Be sure to check out Continuum Audio episodes from this and other issues. And thank you so much to our listeners for joining today. And thank you again, Dr Moore. Dr Moore: Thanks for having me. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Black Swifts are also playfully known as Cloud Swifts, a suitable nickname for one of Canada's most impressive and mysterious birds. Join us above the clouds with researcher and mountain enthusiast, Rémi Torrenta, as he shares Black Swift season updates. He describes meeting Black Swifts at the top of a mountain, shares mind boggling facts about the species, and uplifting stories from a successful season of nest monitoring.For an immersive episode on Black Swift research listen to The Wake-up Call: Black Swift, or watch Of Waterfalls and Wings – Surveying for the Mysterious Black Swift.Help migratory birds simply by drinking Bird-friendly Certified Coffee. When you order from birdsandbeans.ca/warblers Birds and Beans donates to this podcast. Thanks! Rémi Torrenta has always had a passion for wildlife and birds. He obtained a MSc in Ecology in the south of France, and then a PhD at Université de Moncton, NB. After 8 years of work experience with forest birds in eastern Canada, he has been the BC Projects Coordinator for Birds Canada since 2021. Remi delivers Citizen Science programs, as well as various Species at Risk research and monitoring projects, and outreach and education programs in western Canada.Andrea Gress (she/her) secretly thinks Piping Plovers are better than all the other birds...studied Renewable Resource Management at the University of Saskatchewan. She pivoted towards birds, after an internship in South Africa. Upon returning, she worked with Piping Plovers in Saskatchewan, and then as the Ontario Piping Plover Coordinator. Years of sharing her love of plovers with beach goers has turned into a full time communications role with Birds Canada.  Support the show

This is a free preview of a paid episode. To hear more, visit abbieattwoodwellness.substack.comThis might be my favorite conversation we've had on this podcast. It's a conversation I had with Edie Stark (an ED therapist) and Sharon Maxwell (a fat activist and weight-inclusive consultant), and we're answering a very important – very hard – listener question.The essence of it is: “I believe in body liberation and anti-diet culture. But what if I'm just uncomfortable being fat?”Tune in for:* How and why Sharon relates to this listener, and moments where she's worked through this thought* How Ozempic culture impacts the desire for weight loss* What it means to practice self-compassion while living within systemic anti-fatness* Whether changing your body can change discomfort* Times when eating disorder thoughts creep in the most* Discomfort as a signal of something deeper* The role of mental and emotional pain on physical symptoms* Navigating the medical system when it blames body size for everything * SO much more!Support the show: Enjoying this podcast? Please support the show on Substack for bonus episodes, community engagement, and access to "Ask Abbie" at abbieattwoodwellness.substack.com/subscribe Apply for Abbie's Group Membership:Already been at this anti-diet culture thing for a while, but want community and continued learning? Apply for Abbie's monthly membership: https://www.abbieattwoodwellness.com/circle-monthly-groupAbout Edie: Edie Stark, MSc, LCSW is a licensed clinical social worker and the owner of Stark Therapy Group, a psychotherapy group practice specializing in eating disorders, trauma, and anxiety from a humanistic, fat-positive, and inclusive lens. She believes in the value of lived experience being met with clinical knowledge to create a collaborative therapeutic experience for all of the clients. Edie is passionate about Trader Joe's snacks– we talk a little bit about that–dismantling the US healthcare system, and the complete and total takedown of diet culture in no particular order.Learn more at https://starktherapygroup.com/About Sharon:Sharon Maxwell (She/Her) is a mental health advocate and fat activist. She works as a weight inclusive consultant, providing education to treatment centers and healthcare providers on the immense harms of weight stigma. Due to her lived experience facing weight stigma, Sharon provides unique insight and offers practical tools to make treatment centers and healthcare settings safe and accessible for fat folks. Sharon is passionate about breaking down the stigma around eating disorders and working to eradicate societal anti-fat bias. When she's not studying or engaged in her activism work, Sharon can be found exploring San Diego with her dog and her best friend.Read "You Don't Look Anorexic" in New York Times MagazineConnect with Sharon on IG: @heysharonmaxwellLearn more about Sharon: https://www.heysharonmaxwell.com/Social media:Find the show on Instagram: @fullplate.podcastFind Abbie on Instagram: @abbieattwoodwellness Podcast Cover Photography by Anya McInroyPodcast Editing by Brian WaltersThis podcast is ad-free and support comes from your support on Substack. Subscribe HERE.

Today Dominic Bowen hosts David Dunn back on the podcast. They discuss the recent Alaskan Summit and its global implications. Find out more about the symbolic wins for Putin, and which ones they are exactly. The American unpreparedness and what its implications are, what the result is for Ukraine, how the EU decided to respond, transatlantic relations and how they are going to change, and much more!David Dunn is Professor of International Politics and Director of Internationalisation for the College of Social Science at the University of Birmingham. David holds a MSc in International Studies and has a PhD in War Studies. He has diverse research interests that fit largely within the areas of US foreign and security policy, strategic and security studies, and diplomacy and statecraft. He has written extensively on the use of force, transatlantic relations and summit diplomacy. He has also published on the security impact of drone technology. His most recent book, co-authored with Nicholas J. Wheeler is: Drones, Force and Law: European Perspectives (Elements in International Relations) and came out in Jan 2024. Finally, David writes articles for the Conversation. The International Risk Podcast brings you conversations with global experts, frontline practitioners, and senior decision-makers who are shaping how we understand and respond to international risk. From geopolitical volatility and organised crime, to cybersecurity threats and hybrid warfare, each episode explores the forces transforming our world and what smart leaders must do to navigate them. Whether you're a board member, policymaker, or risk professional, The International Risk Podcast delivers actionable insights, sharp analysis, and real-world stories that matter. The International Risk Podcast – Reducing risk by increasing knowledge.Follow us on LinkedIn and Subscribe for all our updates!Tell us what you liked!

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

Aubrey Masango speaks to Inno Motau, President of Young Entrepreneur South Africa (YESA) & Director at MSC Mediterranean Shipping Company who shares insights on her upbringing and how it has shaped the business leader she has become. They also share some anecdotes on growing up in Mamelodi and reflect on their shared experiences.Tags: 702, The Aubrey Masango Show, Aubrey Masango, Profile , Inno Motau, MSC, Shipping, Youth, Leadership, Women, Mamelodi. Pretoria, Business, Entrepreneurship The Aubrey Masango Show is presented by late night radio broadcaster Aubrey Masango. Aubrey hosts in-depth interviews on controversial political issues and chats to experts offering life advice and guidance in areas of psychology, personal finance and more. All Aubrey’s interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from The Aubrey Masango Show. Listen live on weekdays between 20:00 and 24:00 (SA Time) to The Aubrey Masango Show broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk between 20:00 and 21:00 (SA Time) https://buff.ly/NnFM3Nk Find out more about the show here https://buff.ly/lzyKCv0 and get all the catch-up podcasts https://buff.ly/rT6znsn Subscribe to the 702 and CapeTalk Daily and Weekly Newsletters https://buff.ly/v5mfet Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

In this special edition episode, recorded live at the ASCO Annual Meeting, hosts Shikha Jain, MD, and Edward Kim, MD, honor Healio's 2025 Disruptive Innovators for their positive disruption in the field of hematology/oncology, and for pushing the status quo to improve clinical practice.  •    Welcome to the fourth annual Healio Disruptive Innovator Awards in hematology/oncology. 1:00 •    VK Gadi, MD PhD, presents the Health Equity Award. 3:56 •    The Health Equity Award winner, Ana Velázquez Mañana, MD, makes a speech. 6:00 •    Morgan Collier presents the Woman Disruptor of the Year Award. 7:38 •    Betty S. Pace, MD, accepts the Woman Disruptor of the Year Award. 9:19 •    The Social Media Influencer Award, presented by Eleonora Teplinsky, MD. 11:53 •    Amani Jambhekar, MD, also known as @ajvictorymd on Instagram and TikTok, accepts the Social Media Influencer Award. 13:13 •    Brenda M. Nevidjon, MSN, RN, FAAN, presents the Advanced Practice Trailblazer Award. 14:40 •    Ashley Leak Bryant, PhD, RN, OCN, FAAN, delivers her acceptance speech for the Advanced Practice Trailblazer Award. 16:19 •    Kamal Jethwani, MD, MPH, presents the Patient Voice Award. 18:44 •    Founder Kimberly Richardson, MA, accepts the Patient Voice Award for the Black Cancer Collaborative. 20:44 •    Healio's chief content officer, Joan-Marie Stiglich, ELS, presents the NextGen Disruptor Award to Nazli Dizman, MD. 22:22 •    The Clinical Innovation Award goes to UNC Lineberger Comprehensive Cancer Center for their at-home symptom reporting, led by Ethan Basch, MD, MSc. 24:18 •    Hope S. Rugo, MD, wins the Lifetime Disruptor Award. 26:48 •    The Industry Breakthrough Award goes to Breyanzi (lisocabtagene maraleucel, or liso-cel) from Bristol Myers Squibb. 30:57 •    On behalf of Bristol Myers Squibb, Amy Corrao, MSN, NP-C, accepts the Industry Breakthrough Award. 32:33 •    Thanks to all of the winners, nominees and sponsors! 35:39 •    Thanks for listening. 36:21 We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Read the full coverage from Healio's Disruptive Innovators here.

This episode of the Global Hemophilia Report explores the long-overdue conversation about women with hemophilia. Experts discuss the challenges women face in getting diagnosed, the persistent gaps in clinical research and care, and the impact of outdated language and systemic bias. The panel highlights the need for better data, more inclusive clinical trials, and a shift in medical culture to ensure women with hemophilia are recognized and prioritized.    Guests: Michelle Sholzberg MDCM, FRCPC, MSc. Dawn Rotellini Len Valentino, MD Robert Sidonio, Jr., MD   Senior Advisor: Donna DiMichele, MD   Hosted by: Patrick James Lynch   Written by: Kay Vermeil   Featured Advertiser: Sanofi   Subscribe to the Global Hemophilia Report   Show Notes:   Presenting Sponsor: Presented by Sanofi Join Shellye as she shares her inspiring journey as a woman living with hemophilia. After years of unanswered questions, her diagnosis highlights the critical role of health literacy in bridging care gaps. Through advocacy, Shellye raises awareness and empowers underserved communities. Watch her story and see how health literacy can break barriers and transform lives. Click here to watch her story: Sanofi – See Hemophilia Through My Eyes: Women & Girls For too long, women and girls who bleed have been dismissed. Left out of the narrative. Ignored by the system. But not anymore. In our new film, “Dismissed,” meet Isabelle—a 15-year-old with hemophilia who's using her voice to uplift the unheard. Alongside her are four powerful stories of women challenging what's "normal" and demanding recognition, care, and justice. This is more than a film. It's a movement.

Dr. Christopher Timmermann is neuroscientist and co-director of the UCL Centre for Consciousness Research in London. He obtained a BSc in Psychology in Santiago, Chile and an MSc in Cognitive Neuroscience at the University of Bologna in Italy. He was also leading one of the first DMT research groups at Imperial College London.His empirical and theoretical work focuses on the neuroscience, psychiatry, psychology, and beliefs of psychedelics, their relationship to consciousness and applications in mental health. The work he has led has been published in high-regarded journals, and has been widely covered by mass media outlets. He also founded and is the director of an educational non-profit in Chile, the ECOH Foundation.He is the expert on 5MeO DMT right, which has been dubbed the “Mount Everest of psychedelics,” and fittingly, Timmermann writes, “its experiences are often referred to as “whiteouts.” But beyond its ability to eliminate the sense of space and time, its most interesting effect lies in the way it dissolves the self. This is key. The question of whether the self is necessary for consciousness to occur has been debated by philosophers for thousands of years — and it remains unsettled. But with 5MeO, something completely different happens: It radically deconstructs all possible worlds, sparing only awareness.IG: christophertimmermannOUR INFO: IG: @the.newhealthclub @thenewhealthinstitute Website: https://www.thenewhealthinstitute.org/ Hosted on Acast. See acast.com/privacy for more information.

In this episode Dominic Bowen and Yaroslav Lissovolik dive into the challenges and opportunities of BRICS! Find out more about the economic Asymmetries and power dynamics, consensus and decision-making, future strategies, BRICS' role in global governance, Russia's position, future cooperation, BRICS plus, international risks and opportunities, and more!Yaroslav Lissovolik worked in the International Monetary Fund, in Washington, where he was Advisor to the Executive Director for the Russian Federation (2001–2004). In 2004 he joined Deutsche Bank as Chief Economist and became Head of Company Research in Russia in 2009, and then a member of the Management Board of Deutsche Bank in Russia in 2011. In 2015–2018 Yaroslav Lissovolik was Chief Economist and subsequently Managing Director of Research and Member of the Management Board at the Eurasian Development Bank (EDB). From 2018 to 2022 he has been Senior Managing Director — Head of Research at Sberbank Investment Research (CIB). In 2023 he founded BRICS+ Analytics to conduct in-depth research on the future trajectories of BRICS+ development.   Yaroslav Lissovolik graduated from Harvard University (magna cum laude) with a BA degree in Economics, and received an MSc in Economics degree from the London School of Economics (LSE). He also received his PhD degree in Economics from the Moscow State Institute for International Relations (MGIMO, red diploma) and a Doctorate in Economics from the Diplomatic Academy. Yaroslav Lissovolik is also a member of Bretton Woods Committee.  He has published several books and numerous papers on Russia's entry into the WTO, BRICS and other economic policy issues.The International Risk Podcast brings you conversations with global experts, frontline practitioners, and senior decision-makers who are shaping how we understand and respond to international risk. From geopolitical volatility and organised crime, to cybersecurity threats and hybrid warfare, each episode explores the forces transforming our world and what smart leaders must do to navigate them. Whether you're a board member, policymaker, or risk professional, The International Risk Podcast delivers actionable insights, sharp analysis, and real-world stories that matter. The International Risk Podcast – Reducing risk by increasing knowledge.Follow us on LinkedIn and Subscribe for all our updates!Tell us what you liked!

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care," Danielle Andrade, MD, MSc, adult neurologist at the University of Toronto and co-chair of the ILAE Transition Task Force, discussed the critical process of moving pediatric patients with epilepsy into adult care. She highlighted findings from the task force's global survey on transition practices, revealing major differences across regions. Andrade also shared important considerations for students with epilepsy entering college, including lifestyle management and the “perfect storm” of seizure triggers like sleep deprivation, alcohol, and medication adherence. She spoke on the vital role of reproductive health discussions, the utility of readiness questionnaires, and the challenges of coordinating multi-specialty care. Finally, Andrade underscored the importance of clear communication between pediatric and adult neurologists, as well as the need for stronger guidelines and education worldwide. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:00 – Global survey findings on epilepsy transition of care 2:10 – Key considerations for students with epilepsy entering college 3:50 – Ensuring continuity of care during transition into adulthood 5:45 – Neurology News Minute 7:30 – Common challenges and strategies to overcome them 9:30 – Final thoughts on back-to-school care and global survey insights The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Ianalumab Meets Primary End Points in Phase 3 NEPTUNUS Trials of Sjögren's Disease Praxis' Vormatrigine Shows Significant Ability to Reduce Seizure Incidence in Phase 2 RADIANT Study FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about whether small fiber neuropathy is an autoimmune disorder; Merit Cudkowicz, MD, MSc, FAAN, recipient of this year's AAN Lifetime Achievement Award for Clinically Relevant Research; and how neurologist couples pursue work-life balance.

In today's VETgirl online veterinary continuing education podcast, we interview Dr. Nick Jeffery, BVSc, PhD, MSc, DECVS, DECVN, Professor in Neurology and Neurosurgery from Texas A&M on a recent study by Freeman et al entitled “Percutaneous enzymatic chemonucleolysis of intervertebral disks appears safe and effective in treatment of acute-onset paraparesis and paraplegia in small dogs,” published in JAVMA in March 2025. Can the use of intradiscal chondroitinase ABC (often called "CHASE") injections under fluoroscopic-guidance work as a safe, minimally invasive option for small dogs with acute nonambulatory paraparesis or paraplegia, especially when deep pain perception is intact? If you're a general practitioner who sees a lot of down dogs—and especially if you practice in a Dachshund-heavy region—you'll definitely want to tune in.

Ep 333: Transforming airway health & smiles with MARPE featuring Dr. Svitlana Koval, DMD, MSc, BDSThis week on The Untethered Podcast™, Hallie welcomes back Dr. Svitlana Koval, Florida's leading provider of Miniscrew-Assisted Rapid Palatal Expansion (MARPE). Together, they explore the powerful connection between dental expansion, airway health, and facial balance covering MARPE and clear aligner mechanics, Hallie's personal experience with her children's treatment, timelines, post-care, and the transformative outcomes of a holistic approach.If this episode resonates with you, snap a screenshot of you listening and share it on your Instagram Stories! Tag Hallie @halliebulkin and @drsvitlanakoval to spread the word.In this episode, you'll learn:✔️ Clear Aligner (e.g., Invisalign) Journey and Airway Health✔️ Personal Experience with MARPE and Facial Asymmetry✔️ Understanding MARPE: Procedures and Techniques✔️ Comparing Traditional Expanders and MARPE✔️ Timeline and Procedures for Adult Expansion✔️ Understanding Bone Remodeling and Expansion Techniques✔️ Aesthetic Considerations in Orthodontic Treatment✔️ Timeline for Appliance Removal and Bone Fusion✔️ Impact of Expansion on Facial Structure✔️ Addressing Concerns with Mini Screws and TADs✔️ In-Office Procedure Insights and Patient Care✔️ Managing Asymmetries in Facial StructureRELATED EPISODES YOU MIGHT LOVEEp 263: Breathing Easy – Link Between Orthodontics, Speech & Health with Dr. Svitlana Koval & Tiffany ZilbermanEp 331: Inside My MARPE Journey with yours truly, Hallie BulkinABOUT TODAY'S GUESTI am so excited for you to meet Dr. Svitlana Koval! You can hang out with her over on Instagram and check out her practice at drssk.com.✨ FREE TRAINING ALERT – HAPPENING SEPTEMBER 8–10!If you're an SLP, OT, or student… you need to join me for the FREE 3-Day Pediatric Feeding Screening Training. Over 34,000 of your colleagues have done it — now it's your turn!Here's what you'll get when you sign up:4 hours on a certificate of completion (perfect for your renewal hours)My complete pediatric feeding screening packet — development chart, 50-symptom checklist, findings chart & referral formA chance to win one of FOUR full scholarships to the 12-week Feed The Peds® courseGrab your spot here → www.feedthepeds.com/trainingOTHER WAYS TO CONNECT & LEARN

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ.Related Content: Dalbavancin for Treatment of Staphylococcus aureus BacteremiaManagement of Staphylococcus aureus Bacteremia

Gary is joined by Adi Viveash, who recently joined Middlesbrough first team coaching staff and also spent eight years at Chelsea as assistant Academy and assistant reserve team coach before being named Under-18 manager in July 2011. He was promoted to development squad manager in 2014, which saw him lead Chelsea's Under-21s. During his time at Chelsea, among the players Adi had a key hand in developing were Marc Guehi, Conor Gallagher, Callum Hudson-Odoi, Mason Mount and Reece James. His departure from the Blues was confirmed in May 2017 but two months later he was back in work having been named assistant manager at Coventry City. In this interview, Adi gives a unique perspective on life at Chelsea, how the game has changed in the last 10 years, the variables that coaches must take into consideration, how coaches manage elite level players who are on the verge of the first team, plus the difference between first team coaching and development. An extra special thanks to SportsLab360 for teaming up with us on this episode. Since 2016 they've been helping thousands of coaches empower their players to improve their Soccer IQ and decision-making on the pitch. It's one of the easiest and most affordable ways to get more out of your team. We have a special offer for MSC listeners at the halfway point of the interview! Click below to check them out: https://sportslab360.com/